Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
Investor Centre
Investor Centre
>
ASX Announcements
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
23 Sep 2024
Sixth Confirmed Response in Pancreatic Cancer Trial
20 Sep 2024
FDA Fast Track Designation for Narmafotinib
26 Aug 2024
Change of Director's Interest Notice - Dr Chris Burns
26 Aug 2024
Application for quotation of securities - ATX
23 Aug 2024
Results of Annual General Meeting
23 Aug 2024
Managing Director AGM Presentation
21 Aug 2024
Fifth Confirmed Response in ACCENT Trial
12 Aug 2024
Amplia Receives R&D Tax Rebate Totalling $3.2 Million
07 Aug 2024
Granting of Key Patent in Europe and Japan
06 Aug 2024
Additional Patient Response in Pancreatic Cancer Trial
1
2
3
4
5
6
Next
